Date: 2015-11-03
Type of information: R&D agreement
Compound:
Company: BMS (USA - NY) Johns Hopkins Kimmel Cancer Center (USA - MD)
Therapeutic area: Cancer - Oncology
Type agreement: R&D collaboration
Action mechanism:
Disease:
Details: * On November 3, 2015, BMS announced that they have entered into a collaboration agreement with The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as part of BMS’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM research program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy. As part of the I-O RPM program, Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center will conduct a range of early phase clinical studies and BMS will fund positions within The Johns Hopkins University School of Medicine fellowship program. The I-O RPM research program is a multi-institutional initiative with Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute, Moffitt Cancer Center and now the Johns Hopkins Kimmel Cancer Center. I-O RPM builds on BMS’s formation in 2012 of the International Immuno-Oncology Network (II-ON), which is a global collaboration between BMS and academia focused on facilitating the translation of scientific research findings into clinical trials and, eventually, clinical practice. The program focuses on significant areas of high unmet need marked by poor outcomes among patients with rare population malignancies. A rare population malignancy is a subpopulation within a higher incident disease population. These patients have aggressive disease with an increased potential for early metastasis to multiple sites and/or are initially refractory or subject to early recurrences with conventional cancer therapies. Existing clinical research provide a strong rationale for further research into the potential of immunotherapies for these cancers.
Financial terms:
Latest news:
